Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.

We found that bone morphogenetic protein (BMP) 7, a member of the BMP family, was strikingly up-regulated during the development of primary prostatic adenocarcinoma in the conditional Pten deletion mouse model. To determine the relevance of this finding to human prostate cancer, we examined the expression of BMPs and BMP receptors (BMPR) as well as the responsiveness to recombinant human BMP7 in a series of human prostate tumor cell lines. All prostatic cell lines tested expressed variable levels of BMP2, BMP4, and BMP7 and at least two of each type I and II BMPRs. In all cases, BMP7 induced Smad phosphorylation in a dose-dependent manner, with Smad5 activation clearly demonstrable. However, the biological responses to BMP7 were cell type specific. BPH-1, a cell line representing benign prostatic epithelial hyperplasia, was growth arrested at G1. In the bone metastasis-derived PC-3 prostate cancer cells, BMP7 induced epithelial-mesenchymal transdifferentiation with classic changes in morphology, motility, invasiveness, and molecular markers. Finally, BMP7 inhibited serum starvation-induced apoptosis in the LNCaP prostate cancer cell line and more remarkably in its bone metastatic variant C4-2B line. Each of the cell lines influenced by BMP7 was also responsive to BMP2 in a corresponding manner. The antiapoptotic activity of BMP7 in the LNCaP and C4-2B cell lines was not associated with a significant alteration in the levels of the proapoptotic protein Bax or the antiapoptotic proteins Bcl-2, Bcl-xl, and X-linked inhibitor of apoptosis. However, in C4-2B cells but not in LNCaP cells, a starvation-induced decrease in the level of survivin was counteracted by BMP7. Taken together, these findings suggest that BMPs are able to modulate the biological behavior of prostate tumor cells in diverse and cell type-specific manner and point to certain mechanisms by which these secreted signaling molecules may contribute to prostate cancer growth and metastasis.

[1]  F. Hamdy,et al.  Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[2]  M. Urist,et al.  Bone Morphogenetic Protein: The Molecularization of Skeletal System Development , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[4]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[5]  C. Zhong,et al.  Aberration in the Expression of the Retinoid Receptor, RXRα, in Prostate Cancer , 2003 .

[6]  J. Ross,et al.  Survivin and Bcl-2 expression in prostatic adenocarcinomas. , 2009, Archives of pathology & laboratory medicine.

[7]  R. Dahiya,et al.  Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1 , 2007, In Vitro Cellular & Developmental Biology - Animal.

[8]  C. Kao,et al.  Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate‐specific antigen‐producing tumors in athymic and SCID/bg mice using LNCaP and lineage‐derived metastatic sublines , 1998, International journal of cancer.

[9]  I. Asahina,et al.  Human osteogenic protein-1 induces both chondroblastic and osteoblastic differentiation of osteoprogenitor cells derived from newborn rat calvaria , 1993, The Journal of cell biology.

[10]  R. Taichman,et al.  Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein , 2004, Cancer Research.

[11]  I. Asahina,et al.  Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. , 1994, Growth factors.

[12]  R. Russell,et al.  Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. , 1992, British Journal of Cancer.

[13]  P. Weijerman,et al.  Characterization of adult human prostatic epithelial-cells immortalized by polybrene-induced DNA transfection with a plasmid containing an origin-defective sv40-genome. , 1994, International journal of oncology.

[14]  John C. Lee,et al.  Osteogenic protein‐1 (OP‐1, BMP‐7) induces osteoblastic cell differentiation of the pluripotent mesenchymal cell line C2C12 , 2002, Journal of cellular biochemistry.

[15]  B. Hogan,et al.  Bone morphogenetic proteins: multifunctional regulators of vertebrate development. , 1996, Genes & development.

[16]  Anne Vincent-Salomon,et al.  Epithelial–mesenchymal transition in breast cancer development , 2003 .

[17]  C. Arteaga,et al.  p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. , 2002, Journal of cell science.

[18]  F. Hamdy,et al.  Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. , 1998, British Journal of Cancer.

[19]  A. Bergh,et al.  Role of transforming growth factor-beta1 in prostate cancer. , 2001, Microscopy research and technique.

[20]  R. Kalluri,et al.  BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury , 2003, Nature Medicine.

[21]  Teruhiko Yoshida,et al.  Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs , 1997, Oncogene.

[22]  H. Tokunaga,et al.  Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. , 2000, Cancer research.

[23]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[24]  H. Yamanaka,et al.  Increased expression of bone morphogenetic protein‐7 in bone metastatic prostate cancer , 2003, The Prostate.

[25]  G. Karsenty,et al.  The family of bone morphogenetic proteins. , 2000, Kidney international.

[26]  J. Wozney,et al.  Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells , 1994, The Prostate.

[27]  P Roy-Burman,et al.  Genetically defined mouse models that mimic natural aspects of human prostate cancer development. , 2004, Endocrine-related cancer.

[28]  M. Goumans,et al.  Controlling cell fate by bone morphogenetic protein receptors , 2003, Molecular and Cellular Endocrinology.

[29]  R. Voutilainen,et al.  Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocortical cells. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  E. Barrack.  TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. , 1997, The Prostate.

[31]  Z. Hall.  Cancer , 1906, The Hospital.

[32]  S. Vukicevic,et al.  Regulation of BMP‐7 expression by retinoic acid and prostaglandin E2 , 2002, Journal of cellular physiology.

[33]  P. Roy-Burman,et al.  Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. , 2002, Cancer research.

[34]  R. Cardiff,et al.  Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. , 2002, Cancer research.

[35]  E. Barrack.  TGFβ in prostate cancer: A growth inhibitor that can enhance tumorigenicity , 1997 .

[36]  A. Reddi,et al.  Role of morphogenetic proteins in skeletal tissue engineering and regeneration , 1998, Nature Biotechnology.

[37]  T. Ratliff.  BMP Signals Inhibit Proliferation and In Vivo Tumor Growth of Androgen-Insensitive Prostate Carcinoma Cells , 2005 .

[38]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[39]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[40]  A. Bergh,et al.  Role of transforming growth factor‐β1 in prostate cancer , 2001 .

[41]  G. Miller,et al.  The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. , 2000, Cancer research.

[42]  A. Belldegrun,et al.  Lineage relationship between LNCaP and LNCaP‐derived prostate cancer cell lines , 2004, The Prostate.

[43]  R L Vessella,et al.  Bone morphogenetic protein signaling in prostate cancer cell lines , 2004, Journal of cellular biochemistry.

[44]  Jian Zhang,et al.  Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro , 2001, The Prostate.

[45]  A. Schimmer.  Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice , 2004, Cancer Research.

[46]  Gábor Sirokmány,et al.  Central role for Rho in TGF-β1-induced α-smooth muscle actin expression during epithelial-mesenchymal transition , 2003 .

[47]  H. Moses,et al.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. , 2001, Molecular biology of the cell.

[48]  D. Altieri.  Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.

[49]  V. Rosen,et al.  Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  I. Asahina,et al.  Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. , 1996, Experimental cell research.

[51]  C. Eng,et al.  From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. , 2003, Nature reviews. Genetics.

[52]  J. Clemens,et al.  Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. , 2001, Developmental biology.

[53]  Seong-Jin Kim,et al.  Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells , 2004, Oncogene.

[54]  G. Ayala,et al.  Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. , 2002, Cancer research.

[55]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[56]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[57]  Teruhiko Yoshida,et al.  Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. , 1997, Cancer research.

[58]  J. Shay,et al.  Myofibroblast differentiation of normal human keratocytes and hTERT, extended-life human corneal fibroblasts. , 2003, Investigative ophthalmology & visual science.